Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.

Gynecologic oncology - 1 Dec 2012

Avril Stefanie, Hahn Ellen, Specht Katja, Hauptmann Steffen, Höss Cornelia, Kiechle Marion, Höfler Heinz, Schmalfeldt Barbara

Abstract excerpt

OBJECTIVES: Ovarian borderline tumors (BOTs) generally have an excellent prognosis, although recurrences and malignant transformation can occur. Our aim was to compare clinicopathologic features of BOT with clinical outcome. METHODS: In seventy consecutive BOTs clinicopathologic parameters, tumor cell proliferation (Ki67) and in selected cases KRAS, BRAF and p53 mutational status were analyzed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, p53
Share to Neoplasm Invasiveness

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Rate

Source

Identifiers

PMID: 23000388
DOI: 10.1016/j.ygyno.2012.08.027

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.PMID 23000388Read ↗

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Semantic proximity Read ↗

Current update on borderline ovarian neoplasms.Semantic proximity Read ↗

Serous borderline tumours of the ovary.Semantic proximity Read ↗

Survival Analysis of Borderline Ovarian Tumors: A 23-Year Retrospective Study in a Middle Eastern CohortSemantic proximity Read ↗

Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.Semantic proximity Read ↗

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.Semantic proximity Read ↗

Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

The status of epidermal growth factor receptor in borderline ovarian tumours.Semantic proximity Read ↗

When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors.Semantic proximity Read ↗

Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.Semantic proximity Read ↗

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.